

ASX Announcement Spinal Cage FDA Submission Update

SYDNEY 5th December 2023— Allegra Medical Technologies (**Allegra**) (ASX: AMT) advises, further to the Spinal Cage FDA Submission Update, dated 28th September 2023, regarding the additional information requested by the United States Food and Drug Administration (**FDA**) under the 510(k) pathway in respect to the Sr–HT–Gahnite Spinal Cage Device (**Spinal Cage**), Allegra has submitted the informal response to the FDA. The formal submission due date is the 4th February 2024.

Allegra will continue to update the market on any further developments of the Spinal Cage FDA submission.

This announcement has been authorised for release by the CEO of Allegra.

Contact details:

Robyn Slaughter Company Secretary T: +61 2 8072 1435

ABOUT ALLEGRA MEDICAL TECHNOLOGIES:

Allegra Medical Technologies (AMT), a listed biotechnology company on the Australian Securities Exchange (ASX), is at the forefront of innovation in the medical device industry with its pioneering 3D-printed Sr-HT and Sr-HT-Gahnite orthopaedic devices. AMT holds exclusive ownership of this groundbreaking bio ceramic material, along with registered patents and patent applications from the University of Sydney. This versatile material has several applications, including its use as a cervical fusion cage in spinal surgeries, offering safe and effective treatment options for patients. The development of Sr-HT ceramic material began in 2010 at The University of Sydney, demonstrating the bioactivity required for bone regeneration. Subsequently, Sr-HT-Gahnite was developed, featuring bioactivity, biocompatibility, and mechanical properties suitable for load-bearing orthopaedic implants. AMT boasts a dedicated, highly qualified engineering team with a clear mandate to explore, collaborate, and transform early-stage innovations into commercially viable products. Their primary focus currently centres on commercializing the Sr-HT Gahnite Bone substitute.